Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
Favorable safety and tolerability profile related to OCU400 investigational product candidate Initial clinical data from…
AgencyBloc Named Bronze Stevie Award® Winner in 2026 American Business Awards®